GREETING

The company provides medical diagnostic service that detects and quantifies mutant genes without amplification by utilizing Atomic Force Microscopy that has been perfected through 20 years of research and development at POSTECH.

Early diagnosis of recurrence after surgery through blood samples and providing accurate information regarding level of a specific mutated gene are of great help in cancer patient treatment.

Our platform using atomic force microscopy is extremely useful for diagnosing genetic mutations, including liquid biopsy that requires very high sensitivity and specificity.
Such bio-AFM technology can be applied for various biomarkers such as proteins, microRNA, mRNA, and single mutant genes. Growing into a world-leading diagnosis company can be envisaged.